<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sotalol: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sotalol: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sotalol: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9941" href="/d/html/9941.html" rel="external">see "Sotalol: Drug information"</a> and <a class="drug drug_patient" data-topicid="11051" href="/d/html/11051.html" rel="external">see "Sotalol: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709415"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Life-threatening proarrhythmia:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">To minimize the risk of drug-induced arrhythmia, initiate, reinitiate, or uptitrate sotalol in a facility that can provide cardiac resuscitation and continuous ECG monitoring. Sotalol can cause life threatening ventricular tachycardia associated with QT interval prolongation. Do not initiate sotalol therapy if the baseline QTc is longer than 450 msec. If the QT interval prolongs to 500 msec or greater, reduce the dose, lengthen the dosing interval, or discontinue the drug. Calculate CrCl to determine appropriate dosing.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F222498"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Betapace;</li>
<li>Betapace AF;</li>
<li>Sorine [DSC];</li>
<li>Sotylize</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868276"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Sotalol;</li>
<li>DOM-Sotalol [DSC];</li>
<li>JAMP-Sotalol;</li>
<li>MED Sotalol;</li>
<li>PMS-Sotalol;</li>
<li>PRO-Sotalol [DSC];</li>
<li>RATIO-Sotalol;</li>
<li>RIVA-Sotalol [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1055457"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiarrhythmic Agent, Class II</span>;</li>
<li>
<span class="list-set-name">Antiarrhythmic Agent, Class III</span>;</li>
<li>
<span class="list-set-name">Beta-Adrenergic Blocker</span></li></ul></div>
<div class="block don drugH1Div" id="F53462595"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Arrhythmias:</b> Sotalol is indicated for both the treatment of documented life-threatening ventricular arrhythmias (marketed as Betapace/Sorine/Sotylize) and for the maintenance of normal sinus rhythm in patients with symptomatic atrial fibrillation/flutter who are currently in sinus rhythm (marketed as Betapace/Sotylize).</p>
<p style="text-indent:-2em;margin-left:2em;">PNA ≥ 3 days: Oral: <b>Note:</b> Baseline QT<sub>c</sub> interval and CrCl must be determined prior to initiation. Dosage must be adjusted to individual response and tolerance; doses should be initiated or increased in a hospital facility that can provide continuous ECG monitoring, recognition and treatment of life-threatening arrhythmias, and CPR.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Manufacturer's dosing recommendations are based on doses per m<sup>2</sup> (that are equivalent to the doses recommended in adults) and on pediatric pharmacokinetic and pharmacodynamic studies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11240979','lexi-content-ref-Saul.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11240979','lexi-content-ref-Saul.1'])">Ref</a></span>). BSA, rather than body weight, better predicted apparent clearance of sotalol; however, for a given dose per m<sup>2</sup>, a larger drug exposure (larger AUC) and greater pharmacologic effects were observed in smaller subjects (ie, those with BSA &lt;0.33 m<sup>2</sup> versus those with BSA ≥0.33 m<sup>2</sup>). For infants and children ≤2 years of age, the manufacturer recommends a dosage reduction based on an age factor determined from a graph (see below).</p>
<p style="text-indent:-2em;margin-left:4em;">Manufacturer's labeling: The manufacturer recommended pediatric dosage of 30 mg/<b>m</b>
<sup>2</sup>/dose given every 8 hours must be <b>REDUCED</b> by an age-related factor that is obtained from the graph (see graph). First, obtain the patient's age in months; use the graph to determine where the patient's age (on the logarithmic scale) intersects the age factor curve; read the age factor from the Y-axis; then multiply the age factor by the pediatric dose listed below (ie, the dose for children &gt;2 years); this will result in the proper reduction in dose for age. For example, the age factor for a neonate (PNA: 14 days) is 0.5, so the initial dosage would be (0.5 x 30 mg/m<sup>2</sup>/dose) = 15 mg/m<sup>2</sup>/dose given every 8 hours. Similar calculations should be made for dosage titrations; increase dosage gradually, if needed; allow adequate time between dosage increments to achieve new steady-state and to monitor clinical response, heart rate and QT<sub>c</sub> intervals; half-life is prolonged with decreasing age (&lt;2 years), so time to reach new steady-state will increase; for example, the time to reach steady-state in a neonate may be ≥1 week.</p>
                  (<a class="graphic graphic_figure" href="/d/html/78350.html" rel="external">See Age nomogram</a>)
                  <p style="text-indent:-2em;margin-left:2em;">Alternate dosing: Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Initial: 2 mg/kg/day divided every 8 hours; if needed, increase dosage gradually by 1-2 mg/kg/day increments; allow at least 3 days between dosage increments to achieve new steady-state and to monitor clinical response, heart rate, and QT<sub>c</sub> intervals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16198851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16198851'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">Proposed target dose: 4 mg/kg/day divided every 8 hours; <b>Note:</b> It is not necessary to increase to target dosage if desired clinical effect has been achieved at a lower dosage</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity: </b> QT<sub>c</sub> ≥500 msec during initiation period (Betapace AF): Reduce dose or discontinue sotalol.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in manufacturer's labeling; dosing in neonates with renal impairment has not been investigated; use lower doses or increased dosing intervals; closely monitor clinical response, heart rate and QT<sub>c</sub> interval; allow adequate time between dosage increments to achieve new steady-state, since half-life will be prolonged with renal impairment</p></div>
<div class="block dop drugH1Div" id="F222521"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Baseline QT<sub>c</sub> interval and CrCl must be determined prior to initiation. Dosage must be adjusted to individual response and tolerance; doses should be initiated or increased in a hospital facility that can provide continuous ECG monitoring, recognition and treatment of life-threatening arrhythmias, and CPR:</p>
<p style="text-indent:-2em;margin-left:2em;">In pediatric patients, dosing may be based on either BSA (mg/m<sup>2</sup>) or weight (mg/kg); use extra precaution to verify dosing parameters during calculations. Sotalol is indicated for both the treatment of documented life-threatening ventricular arrhythmias (marketed as Betapace/Sorine/Sotylize) and for the maintenance of normal sinus rhythm in patients with symptomatic atrial fibrillation/flutter who are currently in sinus rhythm (marketed as Betapace AF/Sotylize).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Arrhythmias:</b> Oral: Manufacturer's dosing recommendations are based on doses per m<sup>2</sup> (that are equivalent to the doses recommended in adults) and on pediatric pharmacokinetic and pharmacodynamic studies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11240979','lexi-content-ref-Saul.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11240979','lexi-content-ref-Saul.1'])">Ref</a></span>). BSA, rather than body weight, better predicted apparent clearance of sotalol; however, for a given dose per m<sup>2</sup>, a larger drug exposure (larger AUC) and greater pharmacologic effects were observed in smaller subjects (ie, those with BSA &lt;0.33 m<sup>2</sup> versus those with BSA ≥0.33 m<sup>2</sup>). For infants and children ≤2 years of age, the manufacturer recommends a dosage reduction based on an age factor determined from a graph (see below).</p>
<p style="text-indent:-2em;margin-left:6em;">Manufacturer's labeling: <b>Note:</b> Use with extreme caution if QT<sub>c</sub> is &gt;500 msec while receiving sotalol; reduce the dose or discontinue drug if QT<sub>c</sub> &gt;550 msec.</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children ≤2 years: The manufacturer recommended pediatric dosage of 30 mg/<b>m</b>
<sup>2</sup>/dose every 8 hours must be <b>REDUCED</b> using an age-related factor that is obtained from the graph (see graph). First, obtain the patient's age in months; use the graph to determine where the patient's age (on the logarithmic scale) intersects the age factor curve; read the age factor from the Y-axis; then multiply the age factor by the pediatric dose listed below (ie, the dose for children &gt;2 years); this will result in the proper reduction in dose for age. For example, the age factor for an infant 1 month of age is 0.68, so the initial dosage would be (0.68 x 30 mg/m<sup>2</sup>/dose) = 20 mg/m<sup>2</sup>/dose given every 8 hours. Similar calculations should be made for dosage titrations; increase dosage gradually, if needed; allow adequate time between dosage increments to achieve new steady-state and to monitor clinical response, heart rate and QT<sub>c</sub> intervals; half-life is prolonged with decreasing age (&lt;2 years), so time to reach new steady-state will increase.</p>
                  (<a class="graphic graphic_figure" href="/d/html/78350.html" rel="external">See Age nomogram</a>)
                  <p style="text-indent:-2em;margin-left:8em;">Children &gt;2 years and Adolescents: Initial: 30 mg/<b>m</b>
<sup>2</sup>/dose given every 8 hours; increase dosage gradually if needed; allow at least 36 hours between dosage increments to achieve new steady-state and to monitor clinical response, heart rate, and QT<sub>c</sub> intervals; may increase gradually to a maximum of 60 mg/<b>m</b>
<sup>2</sup>/dose given every 8 hours; not to exceed adult doses (usual maximum adult daily dose: 320 mg/<b>day</b>)</p>
<p style="text-indent:-2em;margin-left:6em;">Alternate dosing: Limited data available:</p>
<p style="text-indent:-2em;margin-left:8em;">Initial: Infants, Children, and Adolescents: 2 mg/kg/day divided every 8 hours; if needed, increase dosage gradually by 1 to 2 mg/kg/day increments; allow 3 days between dosage increments to achieve new steady-state and to monitor clinical response, heart rate, and QT<sub>c</sub> intervals; maximum: 10 mg/kg/day (if no limiting side effects occur) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9024748','lexi-content-ref-1729843','lexi-content-ref-16198851','lexi-content-ref-1546649','lexi-content-ref-7560592','lexi-content-ref-8960489','lexi-content-ref-Tipple.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9024748','lexi-content-ref-1729843','lexi-content-ref-16198851','lexi-content-ref-1546649','lexi-content-ref-7560592','lexi-content-ref-8960489','lexi-content-ref-Tipple.1'])">Ref</a></span>); do not exceed adult doses (usual maximum adult daily dose: 320 mg/<b>day</b>)</p>
<p style="text-indent:-2em;margin-left:8em;">Proposed target doses: <b>Note:</b> It is not necessary to increase to target dosage if desired clinical effect has been achieved at a lower dosage.</p>
<p style="text-indent:-2em;margin-left:10em;">Infants and Children 1 month to 6 years: 6 mg/kg/day divided every 8 hours</p>
<p style="text-indent:-2em;margin-left:10em;">Children &gt;6 years and Adolescents: 4 mg/kg/day divided every 8 hours not to exceed adult doses (usual maximum adult daily dose: 320 mg/<b>day</b>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b> Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">QT<sub>c</sub> ≥500 msec during initiation period (Betapace AF, Sotylize): Reduce dose, prolong the dosing interval (Sotylize), or discontinue sotalol.</p>
<p style="text-indent:-2em;margin-left:4em;">QT<sub>c</sub> ≥520 msec (or JT interval ≥430 msec if the QRS &gt;100 msec) during maintenance therapy (Betapace AF): Reduce dose and carefully monitor QT<sub>c</sub> until &lt;520 msec. If QTc interval ≥520 msec on the lowest maintenance dose, discontinue sotalol.</p>
<p style="text-indent:-2em;margin-left:4em;">QT<sub>c</sub> ≥550 msec (Betapace, Sorine): Reduce dose or discontinue sotalol.</p></div>
<div class="block dorp drugH1Div" id="F51160241"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: There are no dosage adjustments provided in manufacturer's labeling; dosing in children with renal impairment has not been investigated; use lower doses or increased dosing intervals; closely monitor clinical response, heart rate and QT<sub>c</sub> interval; allow adequate time between dosage increments to achieve new steady-state, since half-life will be prolonged with renal impairment</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Hemodialysis would be expected to reduce sotalol plasma concentrations because sotalol is not bound to plasma proteins and does not undergo extensive metabolism. According to the manufacturers of Betapace and Sorine, extreme caution should be employed if sotalol is used in patients with renal failure undergoing hemodialysis. According to the manufacturer of Betapace AF and Sotylize, use is contraindicated. Multiple cases of torsades de pointes have been reported when sotalol was used even at low dosages (eg, 80 mg daily) in patients with end-stage renal disease treated with hemodialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8671988']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8671988'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Peritoneal dialysis: Peritoneal dialysis does not remove sotalol; supplemental dose is not necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>). Cases of torsades de pointes have been reported when sotalol was used even at low dosages (eg, 80 mg daily) in patients with end-stage renal disease treated with peritoneal dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9039065','lexi-content-ref-9159848']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9039065','lexi-content-ref-9159848'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51160242"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">All patients: There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely needed because sotalol is not metabolized by the liver.</p></div>
<div class="block doa drugH1Div" id="F222502"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9941" href="/d/html/9941.html" rel="external">see "Sotalol: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note: Baseline QTc interval and CrCl must be determined prior to initiation. If CrCl ≤60 mL/minute, dosing interval adjustment is necessary.</b> When initiating sotalol, patients should be hospitalized for at least 3 days in order to monitor cardiac rhythm and assess for QT prolongation. Proarrhythmic events can occur after initiation of therapy and with each upward dosage adjustment.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aaa58479-cbd0-43a2-bed4-1f23058f82f5">Atrial fibrillation/flutter, symptomatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atrial fibrillation/flutter, symptomatic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance dose: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Initial:</i> 80 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dose adjustment:</i> If initial dose does not reduce frequency of relapse and excessive QTc prolongation does not occur (eg, QTc &lt;500 msec) after 3 days, may increase dose to 120 mg twice daily; may increase dose further after another 3 days to a maximum dose of 160 mg twice daily if response is inadequate and QTc prolongation is not excessive (eg, QTc &lt;500 msec).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV</b> (as substitution for oral sotalol):</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Initial dose:</i> 75 mg infused over 5 hours twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dose adjustment:</i> If initial dose does not reduce frequency of relapse and excessive QTc prolongation does not occur (eg, QTc &lt;500 msec) after 3 days, may increase dose to 112.5 mg twice daily; may increase dose further after another 3 days to a maximum dose of 150 mg twice daily if response is inadequate and QTc prolongation is not excessive (eg, QTc &lt; 500 msec).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Loading dose to initiate therapy or for dose escalation: </b>Not routinely required. This approach consists of a single, initial IV dose administered over 1 hour, followed by oral maintenance dosing beginning 4 to 12 hours later (see table). The IV loading dose is used to quickly achieve maximum steady-state concentrations similar to the targeted oral maintenance dose in order to observe how patients respond in a setting with continuous ECG monitoring. Achieving maximum steady-state concentrations quickly with an IV loading dose may help facilitate faster patient discharge (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32849964','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32849964','lexi-content-ref-manu.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Dosing derived from pharmacokinetic/pharmacodynamic modeling in 15 healthy volunteers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32849964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32849964'])">Ref</a></span>).</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption>
<b>Sotalol IV Loading Dose or Dose Escalation</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">CrCl (mL/minute)<sup>a</sup></p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">Therapy initiation<sup>b</sup>: IV loading dose (mg) when oral maintenance is planned to be:</p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">Therapy escalation<sup>b</sup>: IV loading dose (mg) when increasing the oral maintenance dose from:</p></th>
<th align="center" rowspan="2">
<p style="text-indent:0em;">Minimum delay to start of oral dose (hour)</p></th>
<th align="center" rowspan="2">
<p style="text-indent:0em;">Oral dosing interval (hour)</p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">80 mg<sup>c</sup></p></th>
<th align="center">
<p style="text-indent:0em;">120 mg</p></th>
<th align="center">
<p style="text-indent:0em;">80 to 120 mg</p></th>
<th align="center">
<p style="text-indent:0em;">120 to 160 mg</p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="7">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> Calculate using Cockcroft-Gault formula.</p></td></tr>
<tr>
<td align="center" colspan="7">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> Monitor QTc interval every 15 minutes during the 1-hour infusion and around the T<sub>max</sub> (2 to 4 hours post dose) of oral doses given within the first 24 hours of therapy. If QTc interval prolongs to &gt;500 msec or increases ≥20% from baseline, discontinue sotalol when targeting an oral maintenance dose of 80 mg. When targeting an oral maintenance dose of 120 mg, discontinue sotalol and consider reinitiating to target 80 mg; when reinitiating to target 80 mg, wait at least 1 day in patients with CrCl ≥60 mL/minute (Somberg 2020; manufacturer’s labeling).</p></td></tr>
<tr>
<td align="center" colspan="7">
<p style="text-indent:0em;text-align:left;">
<sup>c</sup> Recommended starting dose.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;90 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">60 mg</p></td>
<td align="center">
<p style="text-indent:0em;">90 mg</p></td>
<td align="center">
<p style="text-indent:0em;">75 mg</p></td>
<td align="center">
<p style="text-indent:0em;">90 mg</p></td>
<td align="center">
<p style="text-indent:0em;">4 hours</p></td>
<td align="center">
<p style="text-indent:0em;">12 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">60 to 90 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">82.5 mg</p></td>
<td align="center">
<p style="text-indent:0em;">125 mg</p></td>
<td align="center">
<p style="text-indent:0em;">82.5 mg</p></td>
<td align="center">
<p style="text-indent:0em;">105 mg</p></td>
<td align="center">
<p style="text-indent:0em;">4 hours</p></td>
<td align="center">
<p style="text-indent:0em;">12 hours</p></td></tr></tbody></table></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="03c02764-7813-41e6-9184-71c42978fdfe">Fetal tachycardia, sustained</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fetal tachycardia, sustained (maternal/transplacental administration) (off-label use):</b>
<b>Oral:</b> Initial: 80 to 160 mg twice daily; may increase dose as needed up to 480 mg/day in 2 to 3 divided doses based on response and tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29246961','lexi-content-ref-21931080','lexi-content-ref-10851210','lexi-content-ref-35770083','lexi-content-ref-9641744','lexi-content-ref-23303470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29246961','lexi-content-ref-21931080','lexi-content-ref-10851210','lexi-content-ref-35770083','lexi-content-ref-9641744','lexi-content-ref-23303470'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9f882e79-d62c-4b63-bf32-63cd49609f40">Supraventricular tachycardia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Supraventricular tachycardia (off-label use): Oral:</b> Initial: 40 to 80 mg every 12 hours; maximum maintenance dose: 160 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26409259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26409259'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2f42c553-e8c4-4b54-98fb-e270b999dc6b">Ventricular arrhythmias</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ventricular arrhythmias:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance dose: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Initial dose:</i> 80 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dose adjustment</i>: If initial dose does not reduce frequency of relapse and excessive QTc prolongation does not occur (eg, QTc &lt;500 msec) after 3 days, may increase dose to 120 mg twice daily; may increase dose further after another 3 days to a usual maximum dose of 160 mg twice daily if response is inadequate and QTc prolongation is not excessive (eg, QTc &lt;500 msec).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV</b> (as substitution for oral sotalol):</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Initial dose:</i> 75 mg infused over 5 hours twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dose adjustment:</i> If initial dose does not reduce frequency of relapse and excessive QTc prolongation does not occur (eg, QTc &lt;500 msec) after 3 days, may increase dose to 112.5 mg twice daily; may increase dose further after another 3 days to a usual maximum dose of 150 mg twice daily if response is inadequate and QTc prolongation is not excessive (eg, QTc &lt;500 msec).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Loading dose to initiate therapy or for dose escalation: </b>Not routinely required. This approach consists of a single, initial IV dose administered over 1 hour, followed by oral maintenance dosing beginning 4 to 12 hours later (see table). The IV loading dose is used to quickly achieve maximum steady-state concentrations similar to the targeted oral maintenance dose in order to observe how patients respond in a setting with continuous ECG monitoring. Achieving maximum steady-state concentrations quickly with an IV loading dose may help facilitate faster patient discharge (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32849964','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32849964','lexi-content-ref-manu.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Dosing derived from pharmacokinetic/pharmacodynamic modeling in 15 healthy volunteers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32849964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32849964'])">Ref</a></span>).</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption>
<b>Sotalol IV Loading Dose or Dose Escalation</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">CrCl (mL/minute)<sup>a</sup></p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">Therapy initiation<sup>b</sup>: IV loading dose (mg) when oral maintenance is planned to be:</p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">Therapy escalation<sup>b</sup>: IV loading dose (mg) when increasing the oral maintenance dose from:</p></th>
<th align="center" rowspan="2">
<p style="text-indent:0em;">Minimum delay to start of oral dose (hour)</p></th>
<th align="center" rowspan="2">
<p style="text-indent:0em;">Oral dosing interval (hour)</p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">80 mg<sup>c</sup></p></th>
<th align="center">
<p style="text-indent:0em;">120 mg</p></th>
<th align="center">
<p style="text-indent:0em;">80 to 120 mg</p></th>
<th align="center">
<p style="text-indent:0em;">120 to 160 mg</p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="7">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> Calculate using Cockcroft-Gault formula.</p></td></tr>
<tr>
<td align="center" colspan="7">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> Monitor QTc interval every 15 minutes during the 1-hour infusion and around the T<sub>max</sub> (2 to 4 hours post dose) of oral doses given within the first 24 hours of therapy. If QTc interval prolongs to &gt;500 msec or increases ≥20% from baseline, discontinue sotalol when targeting an oral maintenance dose of 80 mg. When targeting an oral maintenance dose of 120 mg, discontinue sotalol and consider reinitiating to target 80 mg; when reinitiating to target 80 mg, wait at least 1 day in patients with CrCl ≥60 mL/minute.</p></td></tr>
<tr>
<td align="center" colspan="7">
<p style="text-indent:0em;text-align:left;">
<sup>c</sup> Recommended starting dose.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;90 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">60 mg</p></td>
<td align="center">
<p style="text-indent:0em;">90 mg</p></td>
<td align="center">
<p style="text-indent:0em;">75 mg</p></td>
<td align="center">
<p style="text-indent:0em;">90 mg</p></td>
<td align="center">
<p style="text-indent:0em;">4 hours</p></td>
<td align="center">
<p style="text-indent:0em;">12 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">60 to 90 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">82.5 mg</p></td>
<td align="center">
<p style="text-indent:0em;">125 mg</p></td>
<td align="center">
<p style="text-indent:0em;">82.5 mg</p></td>
<td align="center">
<p style="text-indent:0em;">105 mg</p></td>
<td align="center">
<p style="text-indent:0em;">4 hours</p></td>
<td align="center">
<p style="text-indent:0em;">12 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<b>Sustained monomorphic ventricular tachycardia, hemodynamically stable (off-label use):</b>
<b>IV:</b> 1.5 mg/kg or 100 mg over 5 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956224','lexi-content-ref-7912296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956224','lexi-content-ref-7912296'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Ventricular premature beats, symptomatic (off-label use): Oral:</b>
<i>Initial</i>: 80 mg twice daily; dose may be increased gradually in increments of 80 mg/day up to a maximum dose of 160 mg twice daily; allow 3 days between dose adjustments in order to attain steady-state plasma concentrations and to allow for monitoring of QT intervals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Conversion from oral sotalol to IV sotalol: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Conversion<b> only</b> applies when substituting an oral maintenance dose with an IV dose administered as a 5-hour infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">80 mg oral equivalent to 75 mg IV.</p>
<p style="text-indent:-2em;margin-left:4em;">120 mg oral equivalent to 112.5 mg IV.</p>
<p style="text-indent:-2em;margin-left:4em;">160 mg oral equivalent to 150 mg IV.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990831"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance dose:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Atrial fibrillation/flutter: Oral, IV:</b></p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &gt;60 mL/minute: Administer every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 40 to 60 mL/minute: Administer every 24 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &lt;40 mL/minute: Use is contraindicated.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Ventricular arrhythmia: Oral, IV:</b></p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &gt;60 mL/minute: Administer every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 30 to 60 mL/minute: Administer every 24 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 10 to 29 mL/minute: Administer every 36 to 48 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &lt;10 mL/minute: Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Loading dose to initiate therapy or for dose escalation: </b>
<b>Atrial fibrillation/flutter or </b>
<b>ventricular arrhythmia: </b>
<b>IV:</b> Not routinely required. This approach consists of a single, initial IV dose administered over 1 hour, followed by oral maintenance dosing beginning 4 to 12 hours later depending on kidney function (see table). The IV loading dose is used to quickly achieve maximum steady-state concentrations similar to the targeted oral maintenance dose in order to observe how patients respond in a setting with continuous ECG monitoring. Achieving maximum steady-state concentrations quickly with an IV loading dose may help facilitate faster patient discharge (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32849964','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32849964','lexi-content-ref-manu.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Dosing derived from pharmacokinetic/pharmacodynamic modeling in 15 healthy volunteers. Doses for CrCl &lt;40 mL/minute only apply to patients with ventricular arrhythmias since use of oral therapy is contraindicated in patients with atrial fibrillation/flutter and CrCl &lt;40 mL/minute. Patients with kidney dysfunction will require a higher initial IV dose to test safety and efficacy of the oral sotalol regimen because these patients tend to have higher sotalol concentrations at steady state despite proper dosage adjustments (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32849964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32849964'])">Ref</a></span>).</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption>
<b>Sotalol IV Loading Dose or Dose Escalation</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">CrCl (mL/minute)<sup>a</sup></p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">Therapy initiation<sup>b</sup>: IV loading dose (mg) when oral maintenance is planned to be:</p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">Therapy escalation<sup>b</sup>: IV loading dose (mg) when increasing the oral maintenance dose from:</p></th>
<th align="center" rowspan="2">
<p style="text-indent:0em;">Minimum delay to start of oral dose (hour)</p></th>
<th align="center" rowspan="2">
<p style="text-indent:0em;">Oral dosing interval (hour)</p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">80 mg<sup>c</sup></p></th>
<th align="center">
<p style="text-indent:0em;">120 mg</p></th>
<th align="center">
<p style="text-indent:0em;">80 to 120 mg</p></th>
<th align="center">
<p style="text-indent:0em;">120 to 160 mg</p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="7">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> Calculate using Cockcroft-Gault formula.</p></td></tr>
<tr>
<td align="center" colspan="7">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> Monitor QTc interval every 15 minutes during the 1-hour infusion and around the T<sub>max</sub> (2 to 4 hours post dose) of oral doses given within the first 24 hours of therapy. If QTc interval prolongs to &gt;500 msec or increases ≥20% from baseline, discontinue sotalol when targeting an oral maintenance dose of 80 mg. When targeting an oral maintenance dose of 120 mg, discontinue sotalol and consider reinitiating to target 80 mg; when reinitiating to target 80 mg, wait at least 1 day in patients with CrCl ≥60 mL/minute, at least 3 days in patients with CrCl 30 to &lt;60 mL/minute, and at least 7 days in patients with CrCl 10 to &lt;30 mL/minute (manufacturer’s labeling).</p></td></tr>
<tr>
<td align="center" colspan="7">
<p style="text-indent:0em;text-align:left;">
<sup>c</sup> Recommended starting dose.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;90 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">60 mg</p></td>
<td align="center">
<p style="text-indent:0em;">90 mg</p></td>
<td align="center">
<p style="text-indent:0em;">75 mg</p></td>
<td align="center">
<p style="text-indent:0em;">90 mg</p></td>
<td align="center">
<p style="text-indent:0em;">4 hours</p></td>
<td align="center">
<p style="text-indent:0em;">12 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">60 to 90 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">82.5 mg</p></td>
<td align="center">
<p style="text-indent:0em;">125 mg</p></td>
<td align="center">
<p style="text-indent:0em;">82.5 mg</p></td>
<td align="center">
<p style="text-indent:0em;">105 mg</p></td>
<td align="center">
<p style="text-indent:0em;">4 hours</p></td>
<td align="center">
<p style="text-indent:0em;">12 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">30 to &lt;60 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">75 mg</p></td>
<td align="center">
<p style="text-indent:0em;">112.5 mg</p></td>
<td align="center">
<p style="text-indent:0em;">82.5 mg</p></td>
<td align="center">
<p style="text-indent:0em;">105 mg</p></td>
<td align="center">
<p style="text-indent:0em;">6 hours</p></td>
<td align="center">
<p style="text-indent:0em;">24 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">10 to &lt;30 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">75 mg</p></td>
<td align="center">
<p style="text-indent:0em;">112.5 mg</p></td>
<td align="center">
<p style="text-indent:0em;">82.5 mg</p></td>
<td align="center">
<p style="text-indent:0em;">105 mg</p></td>
<td align="center">
<p style="text-indent:0em;">12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">48 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis</b>
<b>, intermittent (thrice weekly):</b> Dialyzable (20% to 43%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7471612','lexi-content-ref-973960']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7471612','lexi-content-ref-973960'])">Ref</a></span>):<b> Oral, IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Avoid use; consider alternative agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10684532']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10684532'])">Ref</a></span>). Multiple cases of torsades de pointes have been reported when sotalol was used, even at low dosages (eg, 80 mg daily orally) in patients with end-stage kidney disease treated with hemodialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8671988']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8671988'])">Ref</a></span>). In at least one case, QT interval was not corrected by several days of dialysis, suggestive of widely fluctuating and unpredictable tissue and plasma drug concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10684532']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10684532'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b>
<b>Oral, IV: </b>Avoid use; consider alternative agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10684532']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10684532'])">Ref</a></span>). Cases of torsades de pointes have been reported when sotalol was used even at low dosages (eg, 80 mg daily orally) in patients with end-stage kidney disease treated with peritoneal dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9039065','lexi-content-ref-9159848']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9039065','lexi-content-ref-9159848'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IV: </b>Avoid use; consider alternative agent(s), as no pharmacokinetic data are available in this population. Additionally, removal by CRRT can be interrupted by clotting, filter changes, etc. (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IV:</b> Avoid use, consider alternative agent(s), as no pharmacokinetic data are available in the population. Additionally, clearance will vary on PIRRT versus non-PIRRT days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988050"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely because sotalol is not metabolized by the liver.</p></div>
<div class="block adr drugH1Div" id="F222460"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. There is minimal clinical experience with IV sotalol; however, since exposure is similar between IV and oral sotalol, adverse reactions are expected to be similar.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (dose related; 8% to 13%), chest pain (8%), palpitations (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (13% to 16%), fatigue (dose related; 19% to 26%), headache (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (5% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (dose related; 9% to 18%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Complete atrioventricular block (1%), second degree atrioventricular block (1%), torsades de pointes (dose related; ≤4%), ventricular tachycardia (new or worsened: ≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (4%), diarrhea (5% to 6%), nausea and vomiting (6% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Musculoskeletal pain (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual disturbance (5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Sinoatrial arrest, sinus node dysfunction, sinus pause</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Peripheral neuropathy</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Cardiovascular: Cardiac failure, hypotension, prolonged QT interval on ECG, sinus bradycardia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, pruritus, skin photosensitivity</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperlipidemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinophilia, leukopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Altered mental status, ataxia, emotional lability, paralysis, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pulmonary edema</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F222476"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to sotalol or any component of the formulation; bronchial asthma or related bronchospastic conditions; sinus bradycardia (&lt;50 bpm during waking hours); second- or third-degree AV block (unless a functioning pacemaker is present); congenital or acquired long QT syndromes; cardiogenic shock; decompensated heart failure; sick sinus syndrome; serum potassium &lt;4 mEq/L; when used for atrial fibrillation/flutter, initiation of oral sotalol is contraindicated if baseline QTc interval &gt;450 msec or CrCl &lt;40 mL/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Allergic rhinitis; severe sinus node dysfunction; concurrent use with anesthetics that produce myocardial depression.</p></div>
<div class="block war drugH1Div" id="F222457"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bradycardia/hypotension: May cause bradycardia (including heart block) and hypotension. Dose adjustments of agents that slow AV nodal conduction may be necessary when sotalol is initiated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Proarrhythmic effects: <b>[US Boxed Warning]: To minimize the risk of drug-induced arrhythmia, initiate or reinitiate sotalol in a facility that can provide cardiac resuscitation and continuous electrocardiographic (ECG) monitoring. Sotalol can cause life threatening ventricular tachycardia associated with QT interval prolongation. Do not initiate sotalol therapy if the baseline QTc is longer than 450 msec. If the QT interval prolongs to 500 msec or greater, reduce the dose, lengthen the dosing interval, or discontinue the drug. Calculate creatinine clearance to determine appropriate dosing. </b>Some experts will initiate oral therapy on an outpatient basis if the patient is in sinus rhythm provided the QT interval and serum potassium are normal and the patient is not receiving any other QT-interval prolonging medications but require inpatient hospitalization if the patient is in atrial fibrillation (AHA/ACC/HRS [January 2014]). Calculation of CrCl must occur prior to administration of the first dose. Dosage should be adjusted gradually with 3 days between dosing increments to achieve steady-state concentrations, and to allow time to monitor QT intervals. Monitor and adjust dose to prevent QTc prolongation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; if used at all, should be used cautiously with close monitoring. Sotalol is contraindicated in patients with bronchial asthma or related bronchospastic conditions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Conduction abnormality: Consider preexisting conditions such as sick sinus syndrome before initiating.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">• Electrolyte imbalances: Correct electrolyte imbalances before initiating (especially hypokalemia and hypomagnesemia) because these conditions increase the risk of torsades de pointes.</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure (HF): New onset or worsening heart failure may occur during initiation or titration. Use with caution in patients with compensated heart failure; monitor for a worsening of the condition and discontinue if symptoms of heart failure occur. Use is contraindicated in patients with uncontrolled (or decompensated) heart failure.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use with caution in patients with myasthenia gravis; may worsen disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myocardial infarction: Use with caution within the first 2 weeks post-MI, especially in patients with markedly impaired ventricular function (experience limited).</p>
<p style="text-indent:-2em;margin-left:4em;">• Peripheral vascular disease (PVD) and Raynaud disease: Can precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud disease. Use with caution and monitor for progression of arterial obstruction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pheochromocytoma (untreated): Adequate alpha-blockade is required prior to use of any beta-blocker.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: <b>[US Boxed Warning]: Adjust dosing interval based on CrCl to decrease risk of proarrhythmia; QT interval prolongation is directly related to sotalol concentration.</b> CrCl must be calculated with dose initiation and dose increases. When used for atrial fibrillation/flutter, sotalol is contraindicated in patients with CrCl &lt;40 mL/minute.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Bradycardia may be observed more frequently in older adult patients (&gt;65 years of age); dosage reductions may be necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abrupt withdrawal: Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered to avoid acute tachycardia, hypertension, and/or ischemia. Severe exacerbation of angina, ventricular arrhythmias, and myocardial infarction (MI) have been reported following abrupt withdrawal of beta-blocker therapy. Temporary but prompt resumption of beta-blocker therapy may be indicated with worsening of angina or acute coronary insufficiency. When QTc prolongation occurs, consider weighing the risk of abrupt withdrawal of sotalol with the risk of QTc prolongation. Use of an alternative beta-blocker may be indicated if worsening angina or acute coronary insufficiency occurs when sotalol is withdrawn abruptly due to QTc prolongation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.</p></div>
<div class="block foc drugH1Div" id="F222468"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 150 mg/10 mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sotylize: 5 mg/mL (250 mL, 480 mL) [contains sodium benzoate; grape flavor]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Betapace: 80 mg, 120 mg, 160 mg [scored; contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Betapace AF: 80 mg, 120 mg, 160 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sorine: 80 mg [DSC], 120 mg [DSC], 160 mg [DSC], 240 mg [DSC] [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 80 mg, 120 mg, 160 mg, 240 mg</p></div>
<div class="block geq drugH1Div" id="F222453"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F222479"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Sotalol HCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg/10 mL (per mL): $395.52</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Sotylize Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/mL (per mL): $2.59</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Betapace AF Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $17.35</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $23.16</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">160 mg (per each): $28.96</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Betapace Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $30.52</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $40.73</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">160 mg (per each): $50.91</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Sotalol HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $0.23 - $2.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $0.31 - $3.42</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">160 mg (per each): $0.39 - $4.27</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">240 mg (per each): $5.09 - $5.56</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868277"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 80 mg, 160 mg, 240 mg</p></div>
<div class="block exp drugH1Div" id="F222474"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Commercial oral solution is available (5 mg/mL)</p>
<p style="text-indent:-2em;margin-left:2em;">A 5 mg/mL sotalol syrup may be made with Betapace, Sorine, or Betapace AF tablets and Simple Syrup containing sodium benzoate 0.1% (Syrup, NF). Place 120 mL Syrup, NF in a 6-ounce amber plastic (polyethylene terephthalate) prescription bottle; add five Betapace, Sorine, or Betapace AF 120 mg tablets and shake the bottle to wet the tablets. Allow tablets to hydrate for at least 2 hours, then shake intermittently over ≥2 hours until the tablets are completely disintegrated; a dispersion of fine particles (water-insoluble inactive ingredients) in syrup should be obtained. <b>Note:</b> To simplify the disintegration process, tablets can hydrate overnight; tablets may also be crushed, carefully transferred into the bottle and shaken well until a dispersion of fine particles in syrup is obtained. Label "shake well". Stable for 3 months at 15°C to 30°C (59°F to 86°F) and ambient humidity.</p>
<div class="reference">Betapace/Betapace AF prescribing information, Zug, Switzerland: Covis Pharmaceuticals; May 2016.</div>
<div class="reference">Sorine prescribing information, Upsher-Smith, Minneapolis, MN, 2012.</div>
</div>
<div class="block admp drugH1Div" id="F52613876"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be administered without regard to meals, but should be administered at the same time each day</p></div>
<div class="block adm drugH1Div" id="F222472"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer without regard to meals.</p>
<p style="text-indent:-2em;margin-left:4em;">When used for the management of fetal tachycardia (maternal/transplacental administration; off-label use), oral doses are administered to the mother.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Loading dose to initiate therapy or for dose escalation: Must be diluted prior to administration. Administer over 1 hour.</p>
<p style="text-indent:-2em;margin-left:4em;">Substitution for oral: Must be diluted prior to administration. Administer over 5 hours; may prolong duration of infusion if QT interval prolongs to ≥500 msec.</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodynamically stable monomorphic VT: Administer IV push over 5 minutes; use with caution because of increased risk of adverse events (eg, bradycardia, hypotension, torsade de pointes) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956224']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956224'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F222493"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 25°C (77°F); excursions permitted between 15°C and 30°C (59°F and 86°F). Protect injection from freezing and light.</p></div>
<div class="block usep drugH1Div" id="F53568934"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Betapace, Sorine, Sotylize: Treatment of life-threatening ventricular arrhythmias (eg, sustained ventricular tachycardia) (FDA approved in ages ≥3 days and adults) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Betapace AF, Sotylize: Maintenance of normal sinus rhythm in patients who have highly symptomatic atrial fibrillation and atrial flutter, but who are currently in normal sinus rhythm [not usually for use in patients with paroxysmal atrial fibrillation/flutter that is easily reversed (eg, by Valsalva maneuver)] (FDA approved in ages ≥3 days and adults) </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">
<b>Note:</b> According to the American Heart Association/American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS), sotalol is not effective for conversion of atrial fibrillation to sinus rhythm but may be used to prevent atrial fibrillation (AHA/ACC/HRS [January, 2014]).</p></div>
<div class="block mst drugH1Div" id="F222546"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Sotalol may be confused with Stadol, Sudafed</p>
<p style="text-indent:-2em;margin-left:4em;">Betapace may be confused with Betapace AF</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300075"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F222462"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: QT-prolonging Class III Antiarrhythmics (Highest Risk) may enhance the QTc-prolonging effect of Amiodarone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Amisulpride (Oral).  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even greater risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the serum concentration of Sotalol. Management: Avoid simultaneous administration of sotalol and antacids. Administer antacids 2 hours after sotalol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Beta-Blockers (Nonselective) may enhance the hypoglycemic effect of Antidiabetic Agents. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azithromycin (Systemic): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Azithromycin (Systemic).  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: Beta-Blockers may enhance the adverse/toxic effect of Cannabis. Specifically, the risk of hypoglycemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbetocin: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: May enhance the bradycardic effect of Sotalol. Ceritinib may enhance the QTc-prolonging effect of Sotalol. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroquine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Chloroquine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citalopram: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Citalopram. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Clarithromycin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Clofazimine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClomiPRAMINE: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of CloZAPine.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Dasatinib.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOBUTamine: Beta-Blockers may diminish the therapeutic effect of DOBUTamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Domperidone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxepin-Containing Products: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Doxepin-Containing Products.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of DroPERidol.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entrectinib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPHEDrine (Systemic): Beta-Blockers may diminish the therapeutic effect of EPHEDrine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Nasal): Beta-Blockers (Nonselective) may enhance the hypertensive effect of EPINEPHrine (Nasal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Oral Inhalation): Beta-Blockers (Nonselective) may enhance the hypertensive effect of EPINEPHrine (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Epinephrine (Racemic): Beta-Blockers (Nonselective) may enhance the hypertensive effect of Epinephrine (Racemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Systemic): Beta-Blockers (Nonselective) may enhance the hypertensive effect of EPINEPHrine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erythromycin (Systemic): QT-prolonging Class III Antiarrhythmics (Highest Risk) may enhance the QTc-prolonging effect of Erythromycin (Systemic). Erythromycin (Systemic) may enhance the QTc-prolonging effect of QT-prolonging Class III Antiarrhythmics (Highest Risk).  Management: Avoid concomitant use of erythromycin and class III antiarrhythmic agents. Use of erythromycin with dronedarone is specifically contraindicated.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Escitalopram: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Escitalopram.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etelcalcetide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may diminish the therapeutic effect of Etilefrine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etofylline: Beta-Blockers may diminish the therapeutic effect of Etofylline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: May enhance the QTc-prolonging effect of QT-prolonging Class III Antiarrhythmics (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flecainide: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Flecainide.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Fluorouracil Products.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flupentixol: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Flupentixol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gadobenate Dimeglumine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Gadobenate Dimeglumine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemifloxacin: May enhance the QTc-prolonging effect of QT-prolonging Class III Antiarrhythmics (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this combination. If use is necessary, monitor for QTc interval prolongation and arrhythmias.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grass Pollen Allergen Extract (5 Grass Extract): Beta-Blockers may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). More specifically, Beta-Blockers may inhibit the ability to effectively treat severe allergic reactions to Grass Pollen Allergen Extract (5 Grass Extract) with epinephrine.  Some other effects of epinephrine may be unaffected or even enhanced (e.g., vasoconstriction) during treatment with Beta-Blockers.  Management: Consider alternatives to either grass pollen allergen extract (5 grass extract) or beta-blockers in patients with indications for both agents.  Canadian product labeling specifically lists this combination as contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Halofantrine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Halofantrine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Class III Antiarrhythmics (Highest Risk) may enhance the QTc-prolonging effect of Haloperidol.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imipramine: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotuzumab Ozogamicin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Inotuzumab Ozogamicin.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Insulins: Beta-Blockers (Nonselective) may enhance the hypoglycemic effect of Insulins. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Insulins. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoproterenol: Beta-Blockers may diminish the therapeutic effect of Isoproterenol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Antiarrhythmic Agents (Class III) may enhance the adverse/toxic effect of Lacosamide. Specifically the risk for bradycardia, ventricular tachyarrhythmias, or a prolonged PR interval may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levofloxacin-Containing Products (Systemic): May enhance the QTc-prolonging effect of QT-prolonging Class III Antiarrhythmics (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Class III Antiarrhythmics (Highest Risk) may enhance the QTc-prolonging effect of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the QTc-prolonging effect of Sotalol. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: Beta-Blockers may enhance the adverse/toxic effect of Mavacamten. Specifically, negative inotropic effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meglumine Antimoniate: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: QT-prolonging Class III Antiarrhythmics (Highest Risk) may enhance the QTc-prolonging effect of Methadone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxyflurane: May enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Midostaurin.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: Beta-Blockers may enhance the therapeutic effect of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Moxifloxacin (Systemic): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Moxifloxacin (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: May enhance the hypotensive effect of Beta-Blockers. NIFEdipine may enhance the negative inotropic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Nilotinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrendipine: May enhance the therapeutic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May diminish the therapeutic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of OLANZapine.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: QT-prolonging Class III Antiarrhythmics (Highest Risk) may enhance the QTc-prolonging effect of Ondansetron.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osimertinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Osimertinib.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxytocin: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pacritinib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pentamidine (Systemic).  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pilsicainide: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pilsicainide.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pimozide.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Piperaquine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probucol: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Probucol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propafenone: May enhance the QTc-prolonging effect of QT-prolonging Class III Antiarrhythmics (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propofol: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Indeterminate Risk - Avoid): May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Indeterminate Risk - Caution): May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IA Antiarrhythmics (Highest Risk): May enhance the QTc-prolonging effect of QT-prolonging Class III Antiarrhythmics (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class III Antiarrhythmics (Highest Risk): May enhance the QTc-prolonging effect of other QT-prolonging Class III Antiarrhythmics (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Highest Risk): May enhance the QTc-prolonging effect of QT-prolonging Class III Antiarrhythmics (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Highest Risk): QT-prolonging Class III Antiarrhythmics (Highest Risk) may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk).  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): QT-prolonging Class III Antiarrhythmics (Highest Risk) may enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QT-prolonging Class III Antiarrhythmics (Highest Risk).  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk).  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): QT-prolonging Class III Antiarrhythmics (Highest Risk) may enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QT-prolonging Class III Antiarrhythmics (Highest Risk).  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of QUEtiapine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quizartinib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reserpine: May enhance the bradycardic effect of Beta-Blockers. Reserpine may enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribociclib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Ribociclib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: QT-prolonging Agents (Highest Risk) may enhance the CNS depressant effect of RisperiDONE. QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of RisperiDONE.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: May enhance the bradycardic effect of Beta-Blockers.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparfloxacin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Sparfloxacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Beta-Blockers may enhance the neuromuscular-blocking effect of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Beta-Blockers (Nonselective) may enhance the hypoglycemic effect of Sulfonylureas. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUNItinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of SUNItinib.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: Beta-Blockers may diminish the therapeutic effect of Tasimelteon.  Management: Consider avoiding nighttime administration of beta-blockers during tasimelteon therapy due to the potential for reduced tasimelteon efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terbutaline: May enhance the QTc-prolonging effect of Sotalol. Sotalol may diminish the therapeutic effect of Terbutaline.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Thioridazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Toremifene.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vemurafenib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Vemurafenib.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">White Birch Allergen Extract: Beta-Blockers may enhance the adverse/toxic effect of White Birch Allergen Extract. Specifically, beta-blockers may reduce the effectiveness of beta-agonists that may be required to treat systemic reactions to white birch allergen extract. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F222494"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">Sotalol peak serum concentrations may be decreased if taken with food. Management: Administer without regard to meals.</p></div>
<div class="block rep_considerations drugH1Div" id="F54342472"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Erectile dysfunction is noted in product labeling following use of sotalol. As a class, outcomes from available studies evaluating beta-blockers and sexual dysfunction are inconsistent, and the negative effects on erectile function are considered controversial. A clear relationship between use of beta-blockers and erectile dysfunction has not been established. Patients on a beta-blocker presenting with sexual dysfunction should be evaluated for underlying disease (Farmakis 2021; Levine 2012; Semet 2017; Terentes-Printzios 2022; Viigimaa 2020).</p></div>
<div class="block pri drugH1Div" id="F222480"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Sotalol crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Adverse fetal/neonatal events have been reported with beta-blockers as a class. If maternal use of a beta-blocker is needed, monitor fetal growth during pregnancy; monitor the newborn for 48 hours after delivery for bradycardia, hypoglycemia, and respiratory depression (ESC [Regitz-Zagrosek 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, renal clearance of sotalol is increased during pregnancy (O’Hare 1983).</p>
<p style="text-indent:0em;margin-top:2em;">Because sotalol crosses the placenta in concentrations similar to maternal serum, it has been studied for the treatment of sustained fetal tachycardia. Sotalol may be considered for the in utero management of fetal supraventricular tachycardia (SVT) or atrial flutter with hydrops or ventricular dysfunction. In cases of SVT without hydrops or ventricular dysfunction, sotalol may be considered if fetal heart rate is ≥200 bpm. Sotalol may also be used for in utero treatment of atrial flutter, and other rare tachycardias with an average fetal heart rate of ≥200 bpm. In addition, sotalol may be considered for fetal ventricular tachycardia (VT) with normal QTc with or without hydrops but is contraindicated for the treatment of fetal VT when long QT syndrome is suspected or confirmed (AHA [Donofrio 2014]).</p>
<p style="text-indent:0em;margin-top:2em;">Sotalol may be used for the treatment of maternal ventricular arrhythmias, atrial fibrillation/atrial flutter, or supraventricular tachycardia during pregnancy; consult current guidelines for specific recommendations (ACC/AHA/HRS [Page 2015]; ESC [Regitz-Zagrosek 2018]).</p></div>
<div class="block mopp drugH1Div" id="F53568919"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum creatinine, magnesium, potassium; heart rate, blood pressure; ECG (eg, QT<sub>c</sub> interval, PR interval); <b>Note:</b> Continuous ECG for a minimum of 3 days with initiation of therapy or dosage increase is suggested; however, patients with an increased sotalol half-life (eg, pediatric patients, especially those &lt;2 years of age, or patients with renal impairment) may require longer monitoring to allow time to achieve steady-state concentrations and observe ECG effect. If baseline QT<sub>c</sub> &gt;450 msec (or JT interval &gt;330 msec if QRS over 100 msec), sotalol (Betapace AF, Sotylize) is contraindicated. </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Betapace AF, Sotylize: In addition, during initiation and dosage titration, monitor the QT interval 2 to 4 hours after each dose. If QT<sub>c</sub> interval is ≥500 msec, reduce dose, prolong the dosing interval (Sotylize), or discontinue sotalol. If the QT<sub>c</sub> interval is &lt;500 msec after 3 days (after fifth or sixth dose in patient receiving once-daily dosing), patient may be discharged on current regimen. Monitor QT<sub>c</sub> interval periodically thereafter.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Consult individual institutional policies and procedures.</p></div>
<div class="block pha drugH1Div" id="F222456"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Beta-blocker which contains both beta-adrenoreceptor-blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) properties </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Class II effects: Increased sinus cycle length, slowed heart rate, decreased AV nodal conduction, and increased AV nodal refractoriness Sotalol has both beta<sub>1</sub>- and beta<sub>2</sub>-receptor blocking activity. The beta-blocking effect of sotalol is a noncardioselective (half maximal at about 80 mg/day and maximal at doses of 320 to 640 mg/day). Significant beta-blockade occurs at oral doses as low as 25 mg/day.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Class III effects: Prolongation of the atrial and ventricular monophasic action potentials, and effective refractory prolongation of atrial muscle, ventricular muscle, and atrioventricular accessory pathways in both the antegrade and retrograde directions. Sotalol is a racemic mixture of <i>d-</i> and <i>l-</i>sotalol; both isomers have similar Class III antiarrhythmic effects while the <i>l-</i>isomer is responsible for virtually all of the beta-blocking activity. The Class III effects are seen only at oral doses ≥160 mg/day. </p></div>
<div class="block phk drugH1Div" id="F222475"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Oral: Rapid; at 1 to 2 hours post dosing (steady-state), reductions in heart rate and cardiac index seen (Winters 1993)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">IV: When administered IV over 5 minutes for ongoing VT, onset of action is ~5 to 10 minutes (Ho 1994)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Oral: Well absorbed (Hanyok 1993); decreased ~20% by meals compared with fasting </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: 1.2 to 2.4 L/kg (Hanyok 1993)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: None </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: None </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Oral: 90% to 100% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Oral:</p>
<p style="text-indent:-2em;margin-left:6em;text-align:justify;">Neonates ≤1 month: 8.4 hours (Saul 2001b)</p>
<p style="text-indent:-2em;margin-left:6em;text-align:justify;">Infants and Children &gt;1 month to 24 months: 7.4 hours (Saul 2001b)</p>
<p style="text-indent:-2em;margin-left:6em;text-align:justify;">Children &gt;2 years to &lt;7 years: 9.1 hours (Saul 2001b)</p>
<p style="text-indent:-2em;margin-left:6em;text-align:justify;">Children 7 to 12 years: 9.2 hours (Saul 2001b)</p>
<p style="text-indent:-2em;margin-left:6em;text-align:justify;">Adults: 12 hours</p>
<p style="text-indent:-2em;margin-left:6em;text-align:justify;">Adults with renal failure (anuric): Up to 69 hours</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">IV: Pharmacokinetics of the IV formulation (administered over 5 hours) are similar to the oral formulations (Somberg 2010)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: Oral: Infants and Children 3 days to 12 years: Mean range: 2 to 3 hours; Adults: 2.5 to 4 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (as unchanged drug)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Clearance (apparent) (Saul 2001b):</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Neonates ≤1 month: 11 mL/minute</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Infants and Children &gt;1 month to 24 months: 32 mL/minute</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Children &gt;2 years to &lt;7 years: 63 mL/minute</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Children 7 to 12 years: 95 mL/minute</p></div>
<div class="block phksp drugH1Div" id="F51221463"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Terminal half-life increases with renal impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038831"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apo-sotalol | Sotacor | Sotalol</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Darob | Ritmic | Sotacor</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Sotacor | Sotahexal | Sotalol-arcana | Sotamed | Sotastad</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo-sotalol | Apx sotalol | Cardol | Cm sotalol | Dbl sotalol | Genrx sotalol | Solavert | Sotab | Sotacor | Sotahexal | Sotalol | Sotalol-bc | Tw sotalol</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Sotalex | Sotalol bexal | Sotalol merck-generics | Sotalol Sandoz</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Darob | Gilucor | Sotagamma | Sotahexal | Sotalex | Sotanorm</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cloridrato de sotalol | Sotacor | Sotahexal</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Sotalex | Sotalol mepha</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Hipecor</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Darob | Ji di | Sotacor | Sotalol | Tan shi | Wei Te | Xi an lin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Darob | Sotacor</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Sotahexal | Sotalex | Sotalol | Sotalol al</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Corsotalol | Darob | Favorex | Gilucor | Jutalex | Rentibloc | Sota | Sota gry | Sota lich | Sota saar | Sota-puren | Sotabeta | Sotagamma | Sotahexal | Sotalex | Sotalodoc | Sotalol | Sotalol acis | Sotalol Actavis | Sotalol al | Sotalol Atid | Sotalol Billix | Sotalol carinopharm | Sotalol Corax | Sotalol ct | Sotalol Ratiopharm | Sotalol Sandoz | Sotalol Vem | Sotalol Winthrop | Sotamerck | Sotaryt | Sotastad | Tachytalol</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Sotacor | Sotalol nm</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Sotaper</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Darob | Loritmik | Sotahexal | Sotalex | Sotalol | Sotastad</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Betacor | Sotaloc</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Sotapor</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Sotacor | Sotalin | Sotalol alpharma | Sotalol generics | Sotalol Merck NM | Sotalol Sandoz</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Sotalex | Sotalol | Sotalol Almus | Sotalol arrow | Sotalol biogaran | Sotalol g gam | Sotalol gnr | Sotalol irex | Sotalol ivax | Sotalol merck | Sotalol ranbaxy | Sotalol Ratiopharm | Sotalol rpg | Sotalol Sandoz | Sotalol teva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Beta Cardone | Sotacor | Sotalol | Sotalol Almus | Sotalol arrow | Sotalol kent | Sotalol Sandoz</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Sotalex | Sotalol | Sotalol/mylan</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo-sotalol | Sotacor</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Darob | Darob mite</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Gilucor | Sotahexal | Sotalex | Sotalol al | Sotalol knoll</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Sotacor</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Beta Cardone | Sotacor | Sotoger</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Sotacor | Sotalol GM</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Solet | Sotalar</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Rytmobeta | Sotalex | Sotalolo | Sotalolo Errekappa</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Sotacor | Sotalol hydrochloride te</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Betalex | Rentibloc | Sotalon</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Sotalol biogaran</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Darob | Sotagamma | Sotalex | Sotalol 1 A pharma | Sotalol al | Sotalol ct | Sotalol mylan | Sotalol Ratiopharm | Sotalol rph | Sotalol teva</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Sotalex</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Darob | Sotagama | Sotagamma | Sotalex | Sotalol | Sotalol 1 A pharma | Sotastad</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Sotalex</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Hipecor | Sotalol | Sotaper</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Sopressor | Sotacor</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Sotacor | Sotalol HCL | Sotalol hcl actavis | Sotalol hcl aurobindo | Sotalol hcl teva | Sotalol hcl tiofarma</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Sotabet | Sotacor | Sotalex | Sotalol</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo-sotalol | Sotacor | Sotalol</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Sotalex</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Biosotal | Darob | Gilucor | Sotahexal | Sotalex | Sotalol | Sotalol aurovitas</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Betapace | Betapace af | Sorine | Sotalol | Sotalol af | Sotalol HCL</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Darob | Sotacor | Sotalol aurobindo</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Darob</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Sotagexal | Sotahexal | Sotalex | Sotalol | Sotalol avexima | Sotalol canon | Tensol</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo-sotalol | Betacor | Pms-sotalol</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Sotacor | Sotalol | Sotalol ebb | Sotalol Merck NM | Sotalol mylan</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo-sotalol | Sotacor | Sotahexal</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Darob</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Sotalex | Sotalol</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Sotacor</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Sotalex | Sotalol mylan</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Darob | Sotarit | Talozin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cardol | Darob | Sotacor | Sotalex</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Gilucor | Soritmik | Sotahexal</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Alosot | Sotacor</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Sotacor | Sotahexal</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-9411221">
<a name="9411221"></a>A Comparison of Antiarrhythmic-Drug Therapy With Implantable Defibrillators in Patients Resuscitated From Near-Fatal Ventricular Arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. <i>N Engl J Med.</i> 1997;337(22):1576-1583.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/9411221/pubmed" id="9411221" target="_blank">9411221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29084731">
<a name="29084731"></a>Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society [published online October 30, 2017]. <i>Circulation</i>. doi: 10.1161/CIR.0000000000000549.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/29084731/pubmed" id="29084731" target="_blank">29084731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29246961">
<a name="29246961"></a>Alsaied T, Baskar S, Fares M, et al. First-line antiarrhythmic transplacental treatment for fetal tachyarrhythmia: a systematic review and meta-analysis. <i>J Am Heart Assoc</i>. 2017;6(12):e007164. doi:10.1161/JAHA.117.007164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/29246961/pubmed" id="29246961" target="_blank">29246961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575676">
<a name="30575676"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 203: chronic hypertension in pregnancy. <i>Obstet Gynecol</i>. 2019;133(1):e26-e50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/30575676/pubmed" id="30575676" target="_blank">30575676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APO-Sotalol.1">
<a name="APO-Sotalol.1"></a>APO-Sotalol (sotalol hydrochloride) tablets BP [product monograph]. Weston, Ontario, Canada: Apotex Inc; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024748">
<a name="9024748"></a>Beaufort-Krol GC, Bink-Boelkens MT. Effectiveness of Sotalol for Atrial Flutter in Children After Surgery for Congenital Heart Disease. <i>Am J Cardiol</i>. 1997;79(1):92-94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/9024748/pubmed" id="9024748" target="_blank">9024748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Betapace.1">
<a name="Betapace.1"></a>Betapace/Betapace AF (sotalol) [prescribing information]. Zug, Switzerland: Covis Pharma; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7471612">
<a name="7471612"></a>Blair AD, Burgess ED, Maxwell BM, Cutler RE. Sotalol kinetics in renal insufficiency. <i>Clin Pharmacol Ther.</i> 1981;29(4):457-463. doi:10.1038/clpt.1981.63<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/7471612/pubmed" id="7471612" target="_blank">7471612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1729843">
<a name="1729843"></a>Colloridi V, Perri C, Ventriglia F, et al. Oral Sotalol in Pediatric Atrial Ectopic Tachycardia. <i>Am Heart J</i>. 1992;123(1):254-256.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/1729843/pubmed" id="1729843" target="_blank">1729843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9039065">
<a name="9039065"></a>Dancey D, Wulffhart Z, McEwan P. Sotalol-induced torsades de pointes in patients with renal failure. <i>Can J Cardiol</i>. 1997;13(1):55-58.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/9039065/pubmed" id="9039065" target="_blank">9039065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24763516">
<a name="24763516"></a>Donofrio MT, Moon-Grady AJ, Hornberger LK, et al; American Heart Association Adults With Congenital Heart Disease Joint Committee of the Council on Cardiovascular Disease in the Young and Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Council on Cardiovascular and Stroke Nursing. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. <i>Circulation</i>. 2014;129(21):2183-2242. doi:10.1161/01.cir.0000437597.44550.5d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/24763516/pubmed" id="24763516" target="_blank">24763516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7046334">
<a name="7046334"></a>Erkkola R, Lammintausta R, Liukko P, Anttila M. Transfer of propranolol and sotalol across the human placenta. Their effect on maternal and fetal plasma renin activity. <i>Acta Obstet Gynecol Scand</i>. 1982;61(1):31-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/7046334/pubmed" id="7046334" target="_blank">7046334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33945044">
<a name="33945044"></a>Farmakis IT, Pyrgidis N, Doundoulakis I, Mykoniatis I, Akrivos E, Giannakoulas G. Effects of major antihypertensive drug classes on erectile function: a network meta-analysis. <i>Cardiovasc Drugs Ther</i>. 2022;36(5):903-914. doi:10.1007/s10557-021-07197-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/33945044/pubmed" id="33945044" target="_blank">33945044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956217">
<a name="20956217"></a>Field JM, Hazinski MF, Sayre MR, et al. Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18)(suppl 3):S640-S656.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/20956217/pubmed" id="20956217" target="_blank">20956217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6867180">
<a name="6867180"></a>Foster CA, Aston SJ. Propranolol-Epinephrine Interaction: A Potential Disaster. <i>Plast Reconstr Surg</i>. 1983;72(1):74-78.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/6867180/pubmed" id="6867180" target="_blank">6867180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi:10.1210/jc.2015-4061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2306424">
<a name="2306424"></a>Hackett LP, Wojnar-Horton RE, Dusci LJ, et al. Excretion of Sotalol in Breast Milk. <i>Br J Clin Pharmacol</i>. 1990;29(2):277-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/2306424/pubmed" id="2306424" target="_blank">2306424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8346722">
<a name="8346722"></a>Hanyok JJ. Clinical pharmacokinetics of sotalol. <i>Am J Cardiol</i>. 1993;72:19A-26A.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/8346722/pubmed" id="8346722" target="_blank">8346722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28833310">
<a name="28833310"></a>Hill GD, Kovach JR, Saudek DE, Singh AK, Wehrheim K, Frommelt MA. Transplacental treatment of fetal tachycardia: a systematic review and meta-analysis. <i>Prenat Diagn</i>. 2017;37(11):1076-1083. doi:10.1002/pd.5144<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/28833310/pubmed" id="28833310" target="_blank">28833310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7737227">
<a name="7737227"></a>Ho DS, Zecchin RP, Cooper MJ, Richards DA, Uther JB, Ross DL. Rapid intravenous infusion of d-l sotalol: time to onset of effects on ventricular refractoriness, and safety. <i>Eur Heart J</i>. 1995;16(1):81-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/7737227/pubmed" id="7737227" target="_blank">7737227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7912296">
<a name="7912296"></a>Ho DS, Zecchin RP, Richards DA, Uther JB, Ross DL. Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. <i>Lancet</i>. 1994;344(8914):18-23. doi:10.1016/s0140-6736(94)91048-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/7912296/pubmed" id="7912296" target="_blank">7912296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ho.1">
<a name="Ho.1"></a>Ho TK, Moretti ME, Schaeffer JK, et al. Maternal [beta]-blocker usage and breast feeding in the neonate. [Abstract] <i>Pediatric Research</i>. 45(4) (PART 2 OF 2):67A.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8671988">
<a name="8671988"></a>Huynh-Do U, Wahl C, Sulzer M, Bühler H, Keusch G. Torsades de pointes during low-dosage sotalol therapy in haemodialysis patients. <i>Nephrol Dial Transplant.</i> 1996;11(6):1153-1154.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/8671988/pubmed" id="8671988" target="_blank">8671988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8671988">
<a name="8671988"></a>Huynh-Do U, Wahl C, Sulzer M, et al. Torsades de pointes during low-dosage sotalol therapy in haemodialysis patients. <i>Nephrol Dial Transplant</i>. 1996;11(6):1153-1154.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/8671988/pubmed" id="8671988" target="_blank">8671988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21931080">
<a name="21931080"></a>Jaeggi ET, Carvalho JS, De Groot E, et al. Comparison of transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol: results of a nonrandomized multicenter study. <i>Circulation</i>. 2011;124(16):1747-1754. doi:10.1161/CIRCULATIONAHA.111.026120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/21931080/pubmed" id="21931080" target="_blank">21931080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24682347">
<a name="24682347"></a>January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. <i>Circulation</i>. 2014;130(23):e199-e267.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/24682347/pubmed" id="24682347" target="_blank">24682347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30686041">
<a name="30686041"></a>January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation [published online January 28, 2019]. <i>Circulation</i>. doi:10.1161/CIR.0000000000000665<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/30686041/pubmed" id="30686041" target="_blank">30686041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9935007">
<a name="9935007"></a>Kuhlkamp V, Mewis C, Mermi J, et al. Suppression of Sustained Ventricular Tachyarrhythmias: A Comparison of d,1-Sotalol With No Antiarrhythmic Drug Treatment. <i>J Am Coll Cardiol</i>. 1999;33(1):46-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/9935007/pubmed" id="9935007" target="_blank">9935007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16198851">
<a name="16198851"></a>Läer S, Elshoff JP, Meibohm B, et al. Development of a Safe and Effective Pediatric Dosing Regimen for Sotalol Based on Population Pharmacokinetics and Pharmacodynamics in Children With Supraventricular Tachycardia. <i>J Am Coll Cardiol</i>. 2005;46(7):1322-1330.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/16198851/pubmed" id="16198851" target="_blank">16198851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7669259">
<a name="7669259"></a>Lang DM. Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers. <i>Drug Saf</i>. 1995;12(5):299-304.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/7669259/pubmed" id="7669259" target="_blank">7669259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19198819">
<a name="19198819"></a>Lennestål R, Otterblad Olausson P, and Källén B. Maternal Use of Antihypertensive Drugs in Early Pregnancy and Delivery Outcome, Notably the Presence of Congenital Heart Defects in the Infants. <i>Eur J Clin Pharmacol</i>. 2009;65(6):615-625.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/19198819/pubmed" id="19198819" target="_blank">19198819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22267844">
<a name="22267844"></a>Levine GN, Steinke EE, Bakaeen FG, et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Quality of Care and Outcomes Research. Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. <i>Circulation</i>. 2012;125(8):1058-1072. doi:10.1161/CIR.0b013e3182447787<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/22267844/pubmed" id="22267844" target="_blank">22267844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manolis.2018">
<a name="Manolis.2018"></a>Manolis AS. Ventricular premature beats. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 26, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1546649">
<a name="1546649"></a>Maragnes P, Tipple M, Fournier A. Effectiveness of Oral Sotalol for Treatment of Pediatric Arrhythmias. <i>Am J Cardiol</i>. 1992;69(8):751-754.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/1546649/pubmed" id="1546649" target="_blank">1546649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8332150">
<a name="8332150"></a>Mason JW. A Comparison of Seven Antiarrhythmic Drugs in Patients With Ventricular Tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. <i>N Engl J Med</i>. 1993;329(7):452-458.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/8332150/pubmed" id="8332150" target="_blank">8332150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24246403">
<a name="24246403"></a>Namouz-Haddad S, Koren G. Fetal pharmacotherapy 2: fetal arrhythmia. <i>J Obstet Gynaecol Can</i>. 2013;35(11):1023-1027.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/24246403/pubmed" id="24246403" target="_blank">24246403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956224">
<a name="20956224"></a>Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18 suppl 3):s729-s767.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/20956224/pubmed" id="20956224" target="_blank">20956224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6861867">
<a name="6861867"></a>O'Hare MF, Leahey W, Murnaghan GA, et al. Pharmacokinetics of Sotalol During Pregnancy. <i>Eur J Clin Pharmacol</i>. 1983;24(4):521-524.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/6861867/pubmed" id="6861867" target="_blank">6861867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7426541">
<a name="7426541"></a>O'Hare MF, Murnaghan GA, Russell CJ. Sotalol as a Hypotensive Agent in Pregnancy. <i>Br J Obstet Gynaecol</i>. 1980;87(9):814-820.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/7426541/pubmed" id="7426541" target="_blank">7426541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10851210">
<a name="10851210"></a>Oudijk MA, Michon MM, Kleinman CS, et al. Sotalol in the treatment of fetal dysrhythmias. <i>Circulation</i>. 2000;101(23):2721-2726. doi:10.1161/01.cir.101.23.2721<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/10851210/pubmed" id="10851210" target="_blank">10851210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10369848">
<a name="10369848"></a>Pacifico A, Hohnloser SH, Williams JH, et al. Prevention of Implantable-Defibrillator Shocks by Treatment With Sotalol. d,1-Sotalol Implantable Cardioverter-Defibrillator Study Group. <i>N Engl J Med</i>. 1999;340(24):1855-1862.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/10369848/pubmed" id="10369848" target="_blank">10369848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26409259">
<a name="26409259"></a>Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2016;67(13):e27-e115.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/26409259/pubmed" id="26409259" target="_blank">26409259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8960489">
<a name="8960489"></a>Pfammatter JP, Paul T. New Antiarrhythmic Drug in Pediatric Use: Sotalol. <i>Pediatr Cardiol</i>. 1997;18(1):28-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/8960489/pubmed" id="8960489" target="_blank">8960489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7560592">
<a name="7560592"></a>Pfammatter JP, Paul T, Lehmann C, et al. Efficacy and Proarrhythmia of Oral Sotalol in Pediatric Patients. <i>J Am Coll Cardiol</i>. 1995;26(4):1002-1007.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/7560592/pubmed" id="7560592" target="_blank">7560592</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35770083">
<a name="35770083"></a>Qin J, Deng Z, Tang C, et al. Efficacy and safety of various first-line therapeutic strategies for fetal tachycardias: a network meta-analysis and systematic review. <i>Front Pharmacol</i>. 2022;13:935455. doi:10.3389/fphar.2022.935455<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/35770083/pubmed" id="35770083" target="_blank">35770083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10684532">
<a name="10684532"></a>Rizza C, Valderrabano M, Singh BN. Recurrent torsades de pointes after sotalol therapy for symptomatic paroxysmal atrial fibrillation in a patient with end-stage renal disease. <i>J Cardiovasc Pharmacol Ther</i>. 1999;4(2):129-134. doi:10.1177/107424849900400208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/10684532/pubmed" id="10684532" target="_blank">10684532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11240979">
<a name="11240979"></a>Saul JP, Ross B, Schaffer MS, et al. Pharmacokinetics and Pharmacodynamics of Sotalol in a Pediatric Population With Supraventricular and Ventricular Tachyarrhythmia. <i>Clin Pharmacol Ther</i>. 2001a;69(3):145-157.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/11240979/pubmed" id="11240979" target="_blank">11240979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Saul.1">
<a name="Saul.1"></a>Saul JP, Schaffer MS, Karpawich PP, et al. Single-Dose Pharmacokinetics of Sotalol in a Pediatric Population With Supraventricular and/or Ventricular Tachyarrhythmia. <i>J Clin Pharmacol</i>. 2001;41(1):35-43.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28622464">
<a name="28622464"></a>Semet M, Paci M, Saïas-Magnan J,et al. The impact of drugs on male fertility: a review. <i>Andrology</i>. 2017;5(4):640-663. doi:10.1111/andr.12366<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/28622464/pubmed" id="28622464" target="_blank">28622464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22444730">
<a name="22444730"></a>Shah A, Moon-Grady A, Bhogal N, et al. Effectiveness of sotalol as first-line therapy for fetal supraventricular tachyarrhythmias. <i>Am J Cardiol</i>. 2012;109(11):1614-1618. doi:10.1016/j.amjcard.2012.01.388<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/22444730/pubmed" id="22444730" target="_blank">22444730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22433576">
<a name="22433576"></a>Skanes AC, Healey JS, Cairns JA, et al. Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control. <i>Can J Cardiol</i>. 2012;28(2):125-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/22433576/pubmed" id="22433576" target="_blank">22433576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20562595">
<a name="20562595"></a>Somberg JC, Preston RA, Ranade V, Molnar J. Developing a safe intravenous sotalol dosing regimen. <i>Am J Ther</i>. 2010;17(4):365-372.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/20562595/pubmed" id="20562595" target="_blank">20562595</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32849964">
<a name="32849964"></a>Somberg JC, Vinks AA, Dong M, Molnar J. Model-informed development of sotalol loading and dose escalation employing an intravenous infusion. <i>Cardiol Res</i>. 2020;11(5):294-304. doi:10.14740/cr1143<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/32849964/pubmed" id="32849964" target="_blank">32849964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9641744">
<a name="9641744"></a>Sonesson SE, Fouron JC, Wesslen-Eriksson E, et al. Foetal Supraventricular Tachycardia Treated With Sotalol. <i>Acta Paediatr</i>. 1998;87(5):584-587. doi:10.1080/08035259850158335<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/9641744/pubmed" id="9641744" target="_blank">9641744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sorine.1">
<a name="Sorine.1"></a>Sorine (sotalol) [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories LLC; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sotalol.1">
<a name="Sotalol.1"></a>Sotalol hydrochloride injection [prescribing information]. Chicago, IL: Altathera Pharmaceuticals LLC; November 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sotalol.2">
<a name="Sotalol.2"></a>Sotalol hydrochloride injection [product monograph]. Weston, Ontario, Canada: Apotex Inc; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sotylize.1">
<a name="Sotylize.1"></a>Sotylize (sotalol) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals; July 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9159848">
<a name="9159848"></a>Tang S, Lo CY, Lo WK, et al. Sotalol-induced Torsade de pointes in a CAPD patient--successful treatment with intermittent peritoneal dialysis. <i>Perit Dial Int</i>. 1997;17(2):207-208.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/9159848/pubmed" id="9159848" target="_blank">9159848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34331033">
<a name="34331033"></a>Terentes-Printzios D, Ioakeimidis N, Rokkas K, Vlachopoulos C. Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs. <i>Nat Rev Cardiol</i>. 2022;19(1):59-74. doi:10.1038/s41569-021-00593-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/34331033/pubmed" id="34331033" target="_blank">34331033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tipple.1">
<a name="Tipple.1"></a>Tipple M, Sandor G. Efficacy and Safety of Oral Sotalol in Early Infancy. <i>Pacing Clin Electrophysiol</i>. 1991;14(11, pt 2):2062-2065.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/ 1721225 /pubmed" id=" 1721225 " target="_blank"> 1721225 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-973960">
<a name="973960"></a>Tjandramaga TB, Verbeeck R, Thomas J, Verbesselt R, Verberckmoes R, Schepper PJ. The effect of end-stage renal failure and haemodialysis on the elimination kinetics of sotalol. <i>Br J Clin Pharmacol</i>. 1976;3(2):259-265. doi:10.1111/j.1365-2125.1976.tb00601.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/973960/pubmed" id="973960" target="_blank">973960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23303470">
<a name="23303470"></a>van der Heijden LB, Oudijk MA, Manten GT, ter Heide H, Pistorius L, Freund MW. Sotalol as first-line treatment for fetal tachycardia and neonatal follow-up. <i>Ultrasound Obstet Gynecol</i>. 2013;42(3):285-293. doi:10.1002/uog.12390<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/23303470/pubmed" id="23303470" target="_blank">23303470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32073535">
<a name="32073535"></a>Viigimaa M, Vlachopoulos C, Doumas M, et al; European Society of Hypertension Working Group on Sexual Dysfunction. Update of the position paper on arterial hypertension and erectile dysfunction. <i>J Hypertens</i>. 2020;38(7):1220-1234. doi:10.1097/HJH.0000000000002382<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/32073535/pubmed" id="32073535" target="_blank">32073535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1689933">
<a name="1689933"></a>Wagner X, Jouglard J, Moulin M, Miller AM, Petitjean J, Pisapia A. Coadministration of flecainide acetate and sotalol during pregnancy: lack of teratogenic effects, passage across the placenta, and excretion in human breast milk. <i>Am Heart J</i>. 1990;119(3 Pt 1):700-702. doi:10.1016/s0002-8703(05)80306-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/1689933/pubmed" id="1689933" target="_blank">1689933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8691967">
<a name="8691967"></a>Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on Mortality in Patients With Left Ventricular Dysfunction After Recent and Remote Myocardial Infarction. The SWORD Investigators. Survival With Oral d-Sotalol. <i>Lancet</i>. 1996;348(9019):7-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/8691967/pubmed" id="8691967" target="_blank">8691967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8346725">
<a name="8346725"></a>Winters SL, Kukin M, Pe E, et al. Effect of oral sotalol on systemic hemodynamics and programmed electrical stimulation in patients with ventricular arrhythmias and structural heart disease. <i>Am J Cardiol</i>. 1993;72:38A-43A.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/8346725/pubmed" id="8346725" target="_blank">8346725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2871333">
<a name="2871333"></a>Wong DG, Spence JD, Lamki L, et al. Effect of Nonsteroidal Anti-inflammatory Drugs on Control of Hypertension of Beta-Blockers and Diuretics. <i>Lancet</i>. 1986;1(8488):997-1001.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/2871333/pubmed" id="2871333" target="_blank">2871333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1354194">
<a name="1354194"></a>Wynn RL. Dental Nonsteroidal Anti-inflammatory Drugs and Prostaglandin-Based Drug Interactions, Part Two. <i>Gen Dent</i>. 1992;40(2):104, 106, 108.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/1354194/pubmed" id="1354194" target="_blank">1354194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7911769">
<a name="7911769"></a>Wynn RL. Epinephrine Interactions With Beta-Blockers. <i>Gen Dent</i>. 1994;42(1):16, 18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/7911769/pubmed" id="7911769" target="_blank">7911769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16949478">
<a name="16949478"></a>Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). <i>J Am Coll Cardiol.</i> 2006;48(5):247-346.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/16949478/pubmed" id="16949478" target="_blank">16949478</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12802 Version 465.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
